Cardiomyopathy News and Research

RSS

Cardiomyopathy is a group of diseases with primary, usually diffuse, involvement of the myocardium. The myocardial disease is not secondary to ischaemic, valvular, congenital or pericardial disease.

Study sheds light on how HIV medications cause significant damage to fetal hearts

A study by a Wayne State University and Children's Hospital of Michigan, Detroit Medical Center research team is shedding new light on the troubling question of whether the drugs often given to HIV-positive pregnant women can cause significant long-term heart problems for the non-HIV-infected babies they carry.

21 Nov 2014

Study shows how stem cells can help regenerate damaged muscle after heart attack

Delivering stem cell factor directly into damaged heart muscle after a heart attack may help repair and regenerate injured tissue, according to a study led by researchers from Icahn School of Medicine at Mount Sinai presented November 18 at the American Heart Association Scientific Sessions 2014 in Chicago, IL.

19 Nov 2014

Cardiac stem cell treatment restores heart function damaged by Duchenne muscular dystrophy

Researchers at the Cedars-Sinai Heart Institute have found that injections of cardiac stem cells might help reverse heart damage caused by Duchenne muscular dystrophy, potentially resulting in a longer life expectancy for patients with the chronic muscle-wasting disease.

18 Nov 2014

Type 2 diabetes and cardiovascular disease share common risk factors

Type 2 diabetes (T2D) and cardiovascular disease (CVD) appear to have a lot in common. They share risk factors such as obesity and they often occur together. If they also share the same genetic underpinings, then doctors could devise a way to treat them together too.

4 Nov 2014

Hypocalcaemic seizure surveillance highlights UK public health policy failings

The occurrence of 91 confirmed or probable hypocalcaemic seizures in children with vitamin D deficiency over a 2-year period in the UK highlights a failure to promote appropriate supplementation.

30 Oct 2014

UCSD researchers develop novel ultrasound technology to diagnose two heart conditions

Engineers at the University of California, San Diego have determined for the first time the impact of a ring-shaped vortex on transporting blood flow in normal and abnormal ventricles within the human heart. They worked with cardiologists at the Non-Invasive Cardiology Laboratory at Gregorio Marañon Hospital, in Madrid, Spain.

29 Oct 2014

French hospital uses Sophia DDM Platform to improve diagnostic testing of congenital disorders

The Hospices Civils de Lyon, the second-largest University Hospital Network in France, has elected to use the Sophia Genetics Data Driven Medicine (DDM) Platform to support improvements in diagnostic testing for patients suffering from congenital disorders.

24 Oct 2014

New screening tools detect heart and lung disease

Two Michigan high school students, sisters Ilina and Medha Krishen, have developed screening tools using electronic stethoscopes to detect lung and heart disease.

21 Oct 2014

Boehringer Ingelheim announces availability of Striverdi Respimat Inhalation Spray 5 mcg in the U.S.

Boehringer Ingelheim today announced that Striverdi Respimat (olodaterol) Inhalation Spray 5 mcg is now available by prescription in pharmacies across the United States.

8 Oct 2014

Ferring Pharmaceuticals to introduce new cranberry flavor option of PREPOPIK in 2015

Colonoscopy is an important and widely used screening tool for colorectal cancer, but for many patients the bowel-preparation process is more uncomfortable than the procedure itself. To offer an alternative choice in bowel preparation, Ferring Pharmaceuticals Inc. will introduce a new cranberry flavor option of PREPOPIK in January 2015.

7 Oct 2014

Sanofi, MyoKardia partner to develop targeted therapeutics for cardiomyopathies

Sanofi and MyoKardia, Inc., a privately-held company leading the development of precision therapies for genetic heart disease, announced today a worldwide collaboration to discover and develop first-of-its-kind targeted therapeutics for heritable heart diseases known as cardiomyopathies, the most common forms of heart muscle disease.

18 Sep 2014

Adequate levels of vitamin E critical for young, elderly and pregnant women

Amid conflicting reports about the need for vitamin E and how much is enough, a new analysis published today suggests that adequate levels of this essential micronutrient are especially critical for the very young, the elderly, and women who are or may become pregnant.

16 Sep 2014

FDA approves Epaned for treatment of symptomatic and asymptomatic heart failure

Silvergate Pharmaceuticals, Inc., focused on the development and commercialization of innovative and safe medicines for children, today announced that the United States Food and Drug Administration approved Epaned for the treatment of symptomatic heart failure and the treatment of asymptomatic left ventricular dysfunction (to decrease the rate of development of overt heart failure and to reduce hospitalization for heart failure).

9 Sep 2014

Intravenous iron supplement can improve quality of life for iron deficient heart failure patients

Heart failure patients with iron deficiency can experience significant and sustainable improvements in functional capacity and quality of life as well as reduced risk of hospital admission for worsening heart failure by receiving just one to two intravenous doses of an iron supplement, according to the results of a study presented today at ESC Congress 2014.

30 Aug 2014

Investigational LCZ696 drug: A real breakthrough for patients with heart failure

An investigational new heart failure drug could be poised to change the face of cardiology based on Hot Line results presented today at ESC Congress 2014.

30 Aug 2014

New research identifies five medical conditions that contribute to more North Carolina SUD cases

Sudden unexpected death (SUD) results from a malfunction of the heart and causes a rapid loss of blood flow through the body, leading to death. It is a very rapid process and may have few or no known warning signs. The overall survival rate for out-of-hospital arrest is only 5-10%. SUD is responsible for upwards of 450,000 people in the United States each year, with North Carolina experiencing an average of 32 SUD-related deaths each day.

29 Aug 2014

Cardiomyopathy News and Research

Further Reading

Study sheds light on how HIV medications cause significant damage to fetal hearts

Study shows how stem cells can help regenerate damaged muscle after heart attack

Cardiac stem cell treatment restores heart function damaged by Duchenne muscular dystrophy

Type 2 diabetes and cardiovascular disease share common risk factors

Hypocalcaemic seizure surveillance highlights UK public health policy failings

UCSD researchers develop novel ultrasound technology to diagnose two heart conditions

French hospital uses Sophia DDM Platform to improve diagnostic testing of congenital disorders

New screening tools detect heart and lung disease

Boehringer Ingelheim announces availability of Striverdi Respimat Inhalation Spray 5 mcg in the U.S.

Ferring Pharmaceuticals to introduce new cranberry flavor option of PREPOPIK in 2015

Sanofi, MyoKardia partner to develop targeted therapeutics for cardiomyopathies

Adequate levels of vitamin E critical for young, elderly and pregnant women

FDA approves Epaned for treatment of symptomatic and asymptomatic heart failure

Intravenous iron supplement can improve quality of life for iron deficient heart failure patients

Investigational LCZ696 drug: A real breakthrough for patients with heart failure

New research identifies five medical conditions that contribute to more North Carolina SUD cases

New gene therapy protects mice from life-threatening heart condition

Implantable heart devices provide same substantial survival benefit, regardless of race

New Cardio-Oncology Program to keep hearts beating strong throughout breast cancer treatments

Improving care, outcomes for NSTEMI patients linked to higher survival rates

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News